In the past the treatment of acromegaly has largely been limited to the use of conventional X-ray and gamma-ray therapy in most cases, and to transfrontal hypophysectomy in advanced and complicated cases, particularly those with extensive suprasellar extension. While improvement in visual fields, decrease in headache, and cessation of gross acral growth may follow conventional radiation techniques, elevations of plasma growth hormone and abnormal glucose tolerance usually persist (Glick et al. 1965 , Roth et al. 1968 ). The availability of a sensitive specific radioimmunoassay for growth hormone (Hunter & Greenwood 1962 , Glick et al. 1963 ) has demonstrated the need for more potent forms of therapy in most instances of acromegaly. Most investigators (Beck et al. 1965 , Roth 1967 have found that growth hormone levels are frequently elevated in patients who are considered to have clinically inactive disease. Little evidence has been found that spontaneous remission is a frequent occurrence and the once highly accepted doctrine of acromegaly 'burning itself out' is not supported by more sensitive endocrine and metabolic measurements (Glick et al. 1965 , Roth et al. 1968 , Beck et al. 1965 , Roth 1967 , Aron et al. 1966 , Linfoot & Greenwood 1965 ). Thus, the results with conventional methods do not approach those reported following heavy particle pituitary irradiation (Aron et al. 1966 , Garcia et al. 1967 ), hypophysectomy (Ray & Horwith 1964) , transsphenoidal implantation of radioactive isotopes (Joplin et al. 1961 , Hartog et al. 1965 , and cryohypophysectomy (Dashe etal. 1966 ).
Since 1958, 102 patients with active acromegaly have undergone heavy particle pituitary irradiation. Several publications (Lawrence et al. 1962 , Lawrence et al. 1963 ) have reported the effectiveness of heavy particle therapy in producing cessation of acral growth, soft tissue and bony regression as well as improvement in diabetic glucose tolerance and other biochemical changes associated with acromegaly. When the radioimmunoassay became available, it was possible to demonstrate striking and consistent falls in plasma growth hormone following heavy particle therapy (Linfoot & Greenwood 1965 , Garcia et al. 1967 . in acromega before and two or more years after treatmei shaded areas refer to patients whose tests w assumed to be abnormal on clinicalgrounds ofco-existing overt diabetes (tests were not performed). The hatched areas refer to the] ofpatients who had abnormal responses dur insulin, glucose and cortisone glucose tolera or more years previously. A striking significant difference between these tw apparent. The level of the treated further suppressed by the admini; glucose during oral glucose toler; indicating that some hypothalamic control exists in many patients. While impossible to correlate the plasma lev with most clinical features of acromega found some laboratory findings u proved to be helpful. Fig 2 shows the improvement in insulin resistance ai glucose tolerance tests in a large patients studied before and two or after treatment. The lack of improver cortisone-modified glucose tolerance, striking lowering of HGH, is interpret that there is a high incidence of penf pairment of islet cell function in a patients.
The lack of complete suppressibil glucose load has helped distinguish pe low-grade acromegaly from normal su elevated HGH levels due to stress, cest: Nevertheless, a high percentage of I suppress after glucose, but rarely levels. Furthermore, we have founl greater suppression of HGH in the following the administration of hydr preparatory to performing a hydri modified glucose tolerance test. In improvement in headache and decr tissue swelling were seen in thes( Unfortunately, the amount of corticoi to produce this suppression has been hi CORTISONE GLUCOSE It should be pointed out that the fall in circula-T < 0T40 ting growth hormone does not occur abruptly as n = 95n37 one might expect after surgical hypophysectomy, but falls gradually, and maximal changes may not be seen for several years. Since it does not appear to be important to reduce growth hormone 68.E concentration rapidly and since therapeutic \7 75.7 results with heavy particles can be achieved without surgical risk and without producing major hypopituitarism, this therapy' is uniquely advantageous. Only 20% of the patients followed thus 23.2 1 far have required replacement therapy with 13.5 hydrocortisone and thyroid and an additional 5 % PRE POST with thyroid alone. Three patients have become pregnant following successful therapy. The only ilic subjects other complications observed in these 102 nt. The patients were transient change in visual fields in 2 because patients who had previously received two courses actually of conventional radiation, and partial III nerve percentage palsy in one other patient who had also received ing prior conventional radiation. Temporal lobe nce tests epilepsy developed in one early patient who was treated with a somewhat larger aperture and higher dose than has been subsequently found and highly desirable and necessary. The patient has been io groups is satisfactorily managed on anticonvulsive therapy. group was Five patients would be considered partial treatstration of ment failures. These 5 patients all had massive ance tests, tumours and, although relatively large amounts of c pituitary heavy particles were delivered to the centre of the it has been lesions, the tumours were not completely covered. rel of HGH All had some lowering of HGH values, but not to ily, we have the same degree as the optimally treated patients.
vhich have
While the results of heavy particle therapy are significant extremely satisfactory, it is apparent that this nd diabetic therapy should be limited to patients in whom number of there is no significant suprasellar extension. more years Patients with very large sellas cannot be satisment in the factorily treated with the standard rotational in spite of technique and can be adequately treated only with Led to mean a recent modification of the Bragg peak. Patients manent im-who have had prior treatment with conventional icromegalic X-ray or gamma techniques probably should not be treated with heavy particles because of the [ity after a increased risk of radiation damage which atients with necessarily limits the amount of heavy particles ibjects with that can be safely delivered. Finally, therapy rogens, &c. should be limited to patients with clinical and patients do laboratory signs of acromegaly confirmed by to normal elevated growth hormone levels. While there is d an even little correlation between the circulating level of se patients growth hormone and the degree of activity in ocortisone, acromegaly, we have generally felt that lowering ocortisone-the basal growth hormone to 10 ng/ml, or preiterestingly, ferably less, within 12-24 months, represents a reased soft satisfactory result, and in these cases we do not e patients. consider any further form of therapy, since further id required fall in growth hormone occurs with the passage igh. of time. Improvement in glucose tolerance, increased insulin sensitivity and soft tissue regression usually accompany growth hormone ch1nges of this magnitude. However, the most striking changes in soft tissue and bone are observed when the growth hormone levels fall below 5 ng/ml. 
The Use of Yttrium 90 Implantation in the Treatment ofAcromegaly This paper reviews the results of implantation of radioactive gold ('95Au) and yttrium (90Y) in our first 80 patients implanted from 1958 to 1967 inclusive and followed for at least one year. The implantation procedure has been described (Joplin et al. 1961 ) and, as shown in Table 1 , the planned dose to the diaphragma sellm and gland periphery has been increased over these years. We have aimed at adequate treatment of the tumour without inducing hypopituitarism.
1Present address: Department of Medicine, Toronto General Hospital, Toronto, Canada (Hartog et al. 1965) , the overall clinical response is designated as satisfactory, partial or nil. A satisfactory response means full relief of symptoms, visible regression of signs of acromegaly, return to normal of the insulin resistance index (Fraser et al. 1962 ) and/or improvement in glucose tolerance where this is abnormal. A partial response fulffils some but not all ofthese criteria.
Among the whole group, at one year or more following the last implant, 53 % had a satisfactory response and nearly all showed some improvement. Fig 1 shows the outcome for the various irradiation dose subgroups. At our current dose plan of 50,000 rads, about half have had a satisfactory response and all the remainder a partial response. Relief of partsthesim, due presumably to soft tissue changes, has occurred within a few weeks, while reduction in the size of hands and feet has been noticed three months after implant; some changes are still progressive in some of the patients who have been followed for as long as nine years. Headaches were abolished in 20 of 40 patients and improved in all but 2 of the remainder; paresthesix were lost in 18 of 27 patients and improved in all but 5 of the 
